Skip to main content

Scancell Holdings plc

corporate_fare Company Profile

Scancell Holdings plc

SCNLD·OTC·Life Sciences·CIK 0002141116

Scancell Holdings plc is a clinical stage biopharmaceutical company that discovers and develops immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include ImmunoBody, DNA active immunotherapies that encode a protein in the form of a modified antibody; Moditope, a potent peptide active immunotherapy targeting tumour-specific neoantigens through the MHC-II presentation pathway; SCIB1, which is in phase I for adjuvant melanoma; SCIB1/iSCIB1+, which is in Phase III for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy in phase III clinical trials for the treatment of solid tumors, including renal cell carcinoma, head, and neck; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company offers the GlyMab platform, which generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which promotes receptor clustering thereby improving immune signaling. Further, it provides pre-clinical products, such as SC129 and SC2811 for solid tumors; SC27; and GT 200 for ovarian cancer. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.

Scancell Holdings plc (OTC:SCNLD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for SCNLD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 8/10. Recent SEC coverage for SCNLD spans F-4/A.

Recent high-impact activity:

  • Scancell Files Amended F-4 for Neuphoria Merger; Exchange Ratio Set at ~0.37725 ADS per Share

Short Interest & Short Volume

88.40 days to cover

FINRA reported short interest of 49,856 shares in SCNLD as of the October 30, 2026 settlement, a 88.0% decrease from the prior period — about 88.4 days to cover at its recent average daily volume. On November 17, 2026, 100.0% of SCNLD volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)49,856 shares as of October 30, 2026
Change vs prior period▼ 88.0%
Days to cover88.40 at avg daily volume of 564
Daily short volume (FINRA facilities)100.0% of 1,713 shares on November 17, 2026

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

SCNLD files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$1.06 -7.83% today
Market cap
$128.5M
Volume
1.7K (1.0× avg)
3-mo avg 1.6K
Live data · 2026-11-22 03:56 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SCNLD - Latest Insights

SCNLD
Nov 18, 2026, 9:51 PM EST
Filing Type: F-4/A
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $1.06 info
Change: $0 (0%) info
Market Cap: $128.496M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets